A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

GAGome score had 90 percent sensitivity, 51 percent specificity for radiological recurrence, with AUC of 0.73 for nonmetastatic clear-cell renal cell carcinoma.